Literature DB >> 21354571

Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events.

T Sehestedt1, S Lyngbæk, J Eugen-Olsen, J Jeppesen, O Andersen, T W Hansen, A Linneberg, T Jørgensen, S B Haugaard, M H Olsen.   

Abstract

OBJECTIVE: The soluble urokinase plasminogen activator receptor (suPAR) is a plasma marker of low grade inflammation and has been associated with cardiovascular risk. We wanted to investigate whether suPAR was associated with markers of subclinical organ damage.
METHODS: In a population sample of 2038 individuals, aged 41, 51, 61 and 71 years, without diabetes, prior stroke or myocardial infarction, not receiving any cardiovascular, anti-diabetic or lipid-lowering medications, we measured urine albumin/creatinine ratio (UACR), carotid atherosclerotic plaques and carotid/femoral pulse wave-velocity (PWV) together with traditional cardiovascular risk factors and high sensitivity C-reactive protein (hsCRP).
RESULTS: suPAR was significantly associated with the presence of plaques (P = 0.003) and UACR (P < 0.001), but not PWV (P = 0.17) when adjusting for age, gender, systolic blood pressure, cholesterol, plasma glucose, waist/hip ratio, smoking and hsCRP. However, suPAR explained only a small part of the variation in the markers of subclinical organ damage (R(2) 0.02-0.04). During a median follow-up of 12.7 years (5th-95th percentile 5.1-13.4 years) a total of 174 composite endpoints (CEP) of cardiovascular death, non-fatal myocardial infarction and stroke occurred. suPAR was associated with CEP independent of plaques, PWV, UACR, and hsCRP as well as age, gender, systolic blood pressure, cholesterol, plasma glucose, waist/hip ratio and smoking with a standardized hazard ratio of 1.16 (95% confidence interval 1.04-1.28, P = 0.006).
CONCLUSION: suPAR was associated with subclinical organ damage, but predicted cardiovascular events independent of subclinical organ damage, traditional risk factors and hsCRP. Further studies must investigate whether suPAR plays an independent role in the pathogenesis of cardiovascular disease.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21354571     DOI: 10.1016/j.atherosclerosis.2011.01.049

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  32 in total

1.  Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis.

Authors:  Claudio Musetti; Marco Quaglia; Tiziana Cena; Annalisa Chiocchetti; Sara Monti; Nausicaa Clemente; Corrado Magnani; Umberto Dianzani; Piero Stratta
Journal:  J Nephrol       Date:  2014-09-04       Impact factor: 3.902

2.  Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.

Authors:  Tae-Hyun Yoo; Christopher E Pedigo; Johanna Guzman; Mayrin Correa-Medina; Changli Wei; Rodrigo Villarreal; Alla Mitrofanova; Farah Leclercq; Christian Faul; Jing Li; Matthias Kretzler; Robert G Nelson; Markku Lehto; Carol Forsblom; Per-Henrik Groop; Jochen Reiser; George William Burke; Alessia Fornoni; Sandra Merscher
Journal:  J Am Soc Nephrol       Date:  2014-06-12       Impact factor: 10.121

3.  Biomarkers of kidney injury and klotho in patients with atherosclerotic renovascular disease.

Authors:  Moo Yong Park; Sandra M Herrmann; Ahmed Saad; Alfonso Eirin; Hui Tang; Amir Lerman; Stephen C Textor; Lilach O Lerman
Journal:  Clin J Am Soc Nephrol       Date:  2014-12-26       Impact factor: 8.237

4.  Soluble Urokinase Plasminogen Activator Receptor: Genetic Variation and Cardiovascular Disease Risk in Black Adults.

Authors:  Nels C Olson; Laura M Raffield; Anne H Moxley; Tyne W Miller-Fleming; Paul L Auer; Nora Franceschini; Debby Ngo; Timothy A Thornton; Ethan M Lange; Yun Li; Deborah A Nickerson; Neil A Zakai; Robert E Gerszten; Nancy J Cox; Adolfo Correa; Karen L Mohlke; Alexander P Reiner
Journal:  Circ Genom Precis Med       Date:  2021-10-28

5.  Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.

Authors:  Ayman Samman Tahhan; Salim S Hayek; Pratik Sandesara; Jamal Hajjari; Muhammad Hammadah; Wesley T O'Neal; Heval M Kelli; Ayman Alkhoder; Nima Ghasemzadeh; Yi-An Ko; Hiroshi Aida; Mohamad Mazen Gafeer; Naser Abdelhadi; Kareem Hosny Mohammed; Keyur Patel; Shipra Arya; Jochen Reiser; Viola Vaccarino; Laurence Sperling; Arshed Quyyumi
Journal:  Atherosclerosis       Date:  2017-06-08       Impact factor: 5.162

6.  Novel biomarkers of coronary microvascular disease.

Authors:  Olivia Y Hung; Suegene K Lee; Parham Eshtehardi; Habib Samady
Journal:  Future Cardiol       Date:  2016-06-13

7.  Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates.

Authors:  Carlos R Franco Palacios; John C Lieske; Hani M Wadei; Andrew D Rule; Fernando C Fervenza; Nikolay Voskoboev; Vesna D Garovic; Ladan Zand; Mark D Stegall; Fernando G Cosio; Hatem Amer
Journal:  Transplantation       Date:  2013-08-27       Impact factor: 4.939

8.  Detection of suPAR in the Saliva of Healthy Young Adults: Comparison with Plasma Levels.

Authors:  Anna Gustafsson; Vjosa Ajeti; Lennart Ljunggren
Journal:  Biomark Insights       Date:  2011-10-25

9.  Direct intercellular communications dominate the interaction between adipose-derived MSCs and myofibroblasts against cardiac fibrosis.

Authors:  Xiaokang Li; Hui Zhao; Chunxiao Qi; Yang Zeng; Feng Xu; Yanan Du
Journal:  Protein Cell       Date:  2015-08-14       Impact factor: 14.870

10.  NT-proBNP, C-reactive protein and soluble uPAR in a bi-ethnic male population: the SAfrEIC study.

Authors:  Ruan Kruger; Rudolph Schutte; Hugo W Huisman; Peter Hindersson; Michael H Olsen; Jesper Eugen-Olsen; Aletta E Schutte
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.